Evidence map›Paper›PMID 36241697›Full record

Trial reportLeukemia2022

Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.

Robert Seifert, David Kersting, Christoph Rischpler, Patrick Sandach, Justin Ferdinandus, Wolfgang P Fendler, Kambiz Rahbar, Matthias Weckesser, Lale Umutlu, Christine Hanoun and 6 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Robert SeifertDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany. robert.seifert@uk-essen.de.ORCID http://orcid.org/0000-0001-5985-7701
David KerstingDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Christoph RischplerDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Patrick SandachDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Justin FerdinandusDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Wolfgang P FendlerDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Kambiz RahbarDepartment of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Matthias WeckesserDepartment of Nuclear Medicine, University Hospital Münster, Münster, Germany.
Lale UmutluGerman Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
Christine HanounGerman Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
Andreas HüttmannGerman Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.ORCID http://orcid.org/0000-0003-2230-3873
Hans Christian ReinhardtGerman Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.
Bastian von TresckowGerman Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.ORCID http://orcid.org/0000-0003-1410-4487
Ken HerrmannDepartment of Nuclear Medicine, University Hospital Essen, Essen, Germany.ORCID http://orcid.org/0000-0002-9662-7259
Ulrich Dührsen *German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany.ORCID http://orcid.org/0000-0002-4034-9472
Michael Schäfers *Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R) in CD20-positive lymphomas). We hypothesized that PET analysis of all lymphoma manifestations may identify patients who benefitted from treatment intensification. A previously developed neural network was employed for iPET analysis to identify the highest pathological FDG uptake (max-SUV

Indexed as

Fluorodeoxyglucose F18Lymphoma, Non-HodgkinAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinHumansPositron-Emission TomographyPrednisoneRituximabThiamineVincristineCyclophosphamideDoxorubicinFluorodeoxyglucose F18PrednisoneRituximabThiaminethiamine triphosphorateVincristine

Identifiers

PMID36241697
PMCPMC9712103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.